Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | VT-464 |
Synonyms | |
Therapy Description |
VT-464 inhibits CYP17 17,20 lyase activity, resulting in decreased androgen production, which may inhibit growth of androgen-dependent tumors (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
VT-464 | Seviteronel|INO-464 | Hormone - Anti-androgens 29 | Seviteronel (VT-464) is a small molecule inhibitor of CYP17 17,20 lyase activity, resulting in decreased androgen production, which may inhibit growth of androgen-dependent tumors (PMID: 30012563, PMID: 25351916, PMID: 32327394). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | prostate adenocarcinoma | not applicable | VT-464 | Phase I | Actionable | In a Phase I study, VT-464 treatment led to safety and tolerability in patients with castration-resistant prostate adenocarcinoma and resulted in a best response of stable disease in 58% (10/17), a partial response in 6% (1/17), and no complete responses (PMID: 30012563; NCT02361086). | 30012563 |
Unknown unknown | prostate cancer | no benefit | VT-464 | Phase II | Actionable | In a Phase II trial, Seviteronel (VT-464) monotherapy demonstrated an undesirable toxicity profile and limited activity, with only 6% (1/17) of patients with metastatic castration-resistant prostate cancer achieved significant PSA response (PMID: 32327394). | 32327394 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02580448 | Phase Ib/II | VT-464 | A Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients With Advanced Breast Cancer | Completed | USA | 0 |